Discovery of Endomorphin: The Body's Own Mu-Opioid Receptor Activator
Researchers discovered endomorphin-1 and endomorphin-2, the first known endogenous peptides with high selectivity for the mu-opioid receptor.
Quick Facts
What This Study Found
Two novel tetrapeptides, endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), were identified as potent and selective endogenous agonists of the mu-opioid receptor.
Key Numbers
How They Did This
Peptide isolation from bovine brain, receptor binding assays across opioid receptor subtypes (mu, delta, kappa), and functional activity testing to establish selectivity and potency.
Why This Research Matters
This discovery filled a major gap in opioid biology — the missing endogenous ligand for the mu receptor. Understanding the body's own mu-opioid system could lead to pain treatments that mimic natural mechanisms with fewer side effects than morphine.
The Bigger Picture
The discovery of endomorphins completed the picture of endogenous opioid peptide families. Each major opioid receptor now has known natural ligands: enkephalins for delta, dynorphins for kappa, and endomorphins for mu. This has profound implications for pain research, addiction science, and understanding mood regulation.
What This Study Doesn't Tell Us
Initial discovery paper — full physiological roles not yet characterized. Brain distribution and biosynthetic pathway were not fully mapped. The precursor protein for endomorphins remained elusive.
Questions This Raises
- ?What is the precursor protein from which endomorphins are derived?
- ?Could synthetic endomorphin analogs provide pain relief with fewer side effects than morphine?
- ?How do endomorphin levels change in chronic pain conditions?
Trust & Context
- Key Stat:
- First mu-selective endogenous opioids Endomorphin-1 and -2 filled a 20+ year gap as the missing natural ligands for the mu-opioid receptor
- Evidence Grade:
- Published in Nature, one of the highest-impact scientific journals. Landmark discovery with rigorous receptor binding and selectivity characterization.
- Study Age:
- Published in 1997, this seminal discovery has been foundational to subsequent opioid peptide research and remains widely cited.
- Original Title:
- A potent and selective endogenous agonist for the mu-opiate receptor.
- Published In:
- Nature, 386(6624), 499-502 (1997)
- Authors:
- Zadina, J E(2), Hackler, L, Ge, L J, Kastin, A J
- Database ID:
- RPEP-00442
Evidence Hierarchy
Frequently Asked Questions
What are endomorphins?
Endomorphins are small peptides naturally produced in the brain that specifically activate the mu-opioid receptor — the same receptor targeted by morphine. They are the body's own painkillers for this receptor type.
Why was this discovery important?
Scientists had known about the mu-opioid receptor for decades and had found natural peptides for other opioid receptors, but the mu receptor's natural activator was missing. Finding endomorphins completed our understanding of the body's internal pain management system.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00442APA
Zadina, J E; Hackler, L; Ge, L J; Kastin, A J. (1997). A potent and selective endogenous agonist for the mu-opiate receptor.. Nature, 386(6624), 499-502.
MLA
Zadina, J E, et al. "A potent and selective endogenous agonist for the mu-opiate receptor.." Nature, 1997.
RethinkPeptides
RethinkPeptides Research Database. "A potent and selective endogenous agonist for the mu-opiate ..." RPEP-00442. Retrieved from https://rethinkpeptides.com/research/zadina-1997-a-potent-and-selective
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.